Atai Life Sciences N.V. (ATAI)
Company Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company.
It engages in developing various therapeutic candidates that focuses on various mental health disorders.
The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries.
Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD.
The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Country | DE |
IPO Date | Jun 18, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 54 |
CEO | Dr. Srinivas G. Rao M.D., Ph.D. |
Contact Details
Address: Krausenstrasse 9-10 Berlin, DE | |
Website | https://www.atai.life |
Stock Details
Ticker Symbol | ATAI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001840904 |
CUSIP Number | N0731H103 |
ISIN Number | NL0015000DX5 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Srinivas G. Rao M.D., Ph.D. | Co-Founder & Chief Executive Officer |
Anne Johnson | Chief Financial Officer |
Dr. Gerd G. Kochendoerfer Ph.D. | Chief Operating Officer |
Christian Angermayer | Founder & Chairman of the Supervisory Board |
Dr. Glenn Short Ph.D. | Chief Scientific Officer |
Dr. Kevin Craig M.D. | Chief Medical Officer |
Dr. Sahil V. Kirpekar M.D. | Chief Business Officer |
Ryan Barrett J.D. | General Counsel & Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 24, 2025 | 4 | Filing |
Mar 24, 2025 | 4 | Filing |
Mar 24, 2025 | 4 | Filing |
Mar 24, 2025 | 4 | Filing |
Mar 24, 2025 | 4 | Filing |
Mar 24, 2025 | 4 | Filing |
Mar 20, 2025 | 8-K | Current Report |
Mar 19, 2025 | 4 | Filing |
Mar 19, 2025 | 4 | Filing |
Mar 19, 2025 | 4 | Filing |